Last updated on August 2020

A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies


Brief description of study

This is a Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD, and clinical activity of AB154 as monotherapy and in combination with zimberelimab (AB122) in participants with advanced solid malignancies.

Detailed Study Description

This is a Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD, and clinical activity of AB154 as monotherapy and in combination with zimberelimab in participants with advanced solid malignancies. In this dose escalation study, participants will receive AB154 administered intravenously as monotherapy or in combination with zimberelimab. Treatment will continue until progressive disease, unacceptable toxicity, withdrawal of consent, or other reasons for study drug discontinuation occurs.

Clinical Study Identifier: NCT03628677

Find a site near you

Start Over

Darlinghurst, Australia

Darlinghurst, Australia
  Connect »

Principal Investigator

Camperdown, Australia
2.44miles
  Connect »

Scientia Clinical Research

Randwick, Australia
2.73miles
  Connect »

Randwick, Australia

Randwick, Australia
2.81miles
  Connect »

Principal Investigator

North Ryde, Australia
8.28miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.